Core Viewpoint - BetterLife Pharma Inc. has received an ISSUE NOTIFICATION from the US Patent and Trademark Office for its BETR-001 composition of matter patent, which provides strong intellectual property protection until at least 2042 [1][4]. Patent and Intellectual Property - The patent covers various claims related to crystalline forms of BETR-001, its formulations, and isomers [3]. - The composition of matter patent is considered the strongest level of intellectual property coverage for a compound [4]. Product Development - BETR-001 is a non-hallucinogenic neuroplastogen aimed at treating psychiatric and neurological disorders, including depression, anxiety, PTSD, traumatic brain injury, migraines, and neuropathic pain [4][8]. - The company has completed most IND-enabling studies and plans to file for IND and start human trials in H1 2026 [5]. Financial and Shareholder Information - BetterLife has issued a total of 6,473,712 common shares and the same number of share purchase warrants, related to convertible debentures and accrued interest totaling $647,371 [6]. - The share purchase warrants are exercisable at an exercise price of $0.10 per warrant and have varying expiration dates [6]. Company Overview - BetterLife Pharma is focused on developing and commercializing compounds for neuro-psychiatric and neurological disorders, specifically BETR-001 and BETR-002 [7]. - BETR-002 is based on honokiol and is also in preclinical studies, targeting anxiety-related disorders [9]. - The company is exploring strategic alternatives for further development of a drug candidate for viral infections [10].
USPTO Files ISSUE NOTIFICATION for BetterLife's BETR-001 Composition of Matter Patent